The FDA approves Pfizer's (PFE -0.2%) Inlyta for patients with advanced kidney cancer. The...

|By:, SA News Editor

The FDA approves Pfizer's (PFE -0.2%) Inlyta for patients with advanced kidney cancer. The action could dent sales at Onyx Pharmaceuticals (ONXX -1.4%) if Pfizer's treatment is deemed more effective than its own version.